Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis.
Emma Guttman-YasskyPaola FacherisPedro Jesus Gomez-AriasEster Del DucaJoel Correa Da RosaStephan WeidingerRobert BissonnetteApril W ArmstrongJulien SeneschalKilian EyerichYeriel D EstradaSwaroop N BoseDan XuAllshine ChenSvitlana TatulychErman GülerGary ChanKaren M PageUrs KerkmannPublished in: Allergy (2023)
Alongside improvements in clinical signs and symptoms of AD, 12 weeks of abrocitinib treatment resulted in downregulation of genes associated with inflammation, epidermal hyperplasia, and Th2 and Th22 immune responses in the skin of patients with moderate-to-severe AD.